Ductal Carcinoma Management and Outcomes

Ductal carcinoma in situ (DCIS) constitutes a non-invasive precursor to breast cancer in which malignant cells remain confined to the ductal system. Its detection has risen sharply with widespread mammographic screening, presenting both an opportunity to prevent invasive disease and a challenge of overdiagnosis. Management typically involves local excision via mastectomy or breast-conserving surgery, often supplemented by radiotherapy and, in hormone-receptor-positive cases, endocrine therapy. Despite high rates of local control, a subset of DCIS lesions progress to invasive ductal carcinoma (IDC), underscoring the need for reliable prognostic markers. Advances in molecular profiling, imaging and computational pathology are refining risk stratification by identifying genetic alterations, microenvironmental factors and morphological traits associated with progression. Emerging biomarker panels and artificial-intelligence-driven models promise to personalise treatment intensity, aiming to spare low-risk patients from unnecessary interventions while ensuring high-risk cases receive timely therapy. Global efforts are focused on balancing the reduction of invasive breast cancer incidence with minimising the physical and psychological burdens of overtreatment.

Research from Nature Portfolio

Unsupervised analysis of chromatin images has revealed distinct cellular morphologies and spatial arrangements that correlate with disease stage. By applying representation-learning algorithms to high‐resolution tissue microarrays, researchers identified eight reproducible cell states present across normal, pre-invasive and invasive samples. Changes in the proportion and spatial clustering of these states accurately predict progression from DCIS to IDC, offering a stain-free biomarker based solely on chromatin architecture. This approach underscores the potential of deep-learning–driven image analysis to generate objective phenotypic classifiers that could complement existing histopathological grading systems and guide treatment decisions.

Ductal Carcinoma Management and Outcomes publication trend

The graph below shows the total number of articles in ductal carcinoma management and outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Ductal carcinoma in situ (DCIS): Non-invasive breast lesion confined to the ductal system.

Invasive ductal carcinoma (IDC): Cancer that has breached the ductal basement membrane into surrounding tissue.

Tumour-infiltrating lymphocytes (TILs): Immune cells present within and around cancerous tissue reflecting the host response.

Xenograft: Transplantation of human cell lines or tissues into an animal host for in vivo study.

Representation learning: Computational method that derives salient features from complex datasets without manual annotation.

References

1. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduction and Targeted Therapy (2024).
2. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression. Cancer Cell (2023).
3. A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial. The Lancet Digital Health (2024).
4. Unsupervised representation learning of chromatin images identifies changes in cell state and tissue organization in DCIS. Nature Communications (2024).